Pfizer-BioNTech's coronavirus vaccine demonstrated 100% efficacy and sustained antibody responses exceeding those previously reported in vaccinated participants aged 16 to 25 years in a Phase 3 study in adolescents aged 12 to 15 years. These data will soon be submitted to the FDA and EMA for approval of the drug for vaccination of this population.